Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Esperite (voorheen Cryo Save)  /  Esperite 2018: het jaar van de waarheid

Esperite (voorheen Cryo Save)« Terug naar discussie overzicht

Esperite 2018: het jaar van de waarheid

Volgen
3.239 Posts
Pagina: «« 1 ... 87 88 89 90 91 ... 162 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 19 juni 2018 16:52
    weer hele vreemde orders:
    ----------------------------------------------------

    Best of Book
    Active as of 19 Jun 2018 16:10 CET
    # orders
    # shares
    Bid price
    Ask price

    # shares
    # orders

    1 1.453 0,3155 ------- 0,318 1.939 1
    1 1.453 0,315 ------- 0,3185 1.699 1
    1 1.453 0,3145 ------- 0,319 1.699 1
    1 1.453 0,314 ------- 0,3195 1.699 1
    -----------------------------------------------------------
    4 5.812 Total 7.036 4

    www.euronext.com/nl/products/equities...
  4. forum rang 6 ff_relativeren 19 juni 2018 18:48
    quote:

    DeZwarteRidder schreef op 19 juni 2018 18:45:

    Ik denk dat Amar allang de cijfers klaar heeft, maar de accountant wil nog geen positieve verklaring geven omdat eerst de nieuwe emissie goedgekeurd moet worden.

    Dus eerst een BAVA en dan misschien de jaarcijfers.
    De cijfers over 2017 hebben m.i. niets te maken met een mega emissie in de 2e helft van 2018.
  5. forum rang 10 DeZwarteRidder 19 juni 2018 18:52
    quote:

    ff_relativeren schreef op 19 juni 2018 18:48:

    [...]De cijfers over 2017 hebben m.i. niets te maken met een mega emissie in de 2e helft van 2018.
    Toch wel, dit heeft te maken met een negatief eigen vermogen en met de going-concern-verklaring.
    De accountant wil dus zeker weten dat het eigen vermogen weer positief wordt.

    Vergeet ook niet dat de oude emissie nog niet eens helemaal klaar is. De oude emissie is dus niet voldoende om het eigen vermogen weer positief te maken.
  6. forum rang 5 Bromsnor 19 juni 2018 19:15
    quote:

    ff_relativeren schreef op 19 juni 2018 15:49:

    [...]
    Wie er nog geld op tafel legt ? De partij die 6% korting krijgt op de lopende beurskoers !
    Beurskoers -/- uitoefenprijs = direkte winst bij dumpen van de emissie-aandelen.

    Gebeurde destijds ook bij Antonov, de grootste blunder (belegging) van mij ooit.
    Boef Marius Ritskes kreeg ook korting (12%) bij een donatie aan het bedrijf met zijn Quivest.
    Nog dezelfde dag dumpte hij zijn aandelen op de beurs.
    Verwatering op verwatering.
  7. forum rang 10 DeZwarteRidder 19 juni 2018 19:40
    quote:

    Winststrever schreef op 19 juni 2018 19:15:

    [...]
    Gebeurde destijds ook bij Antonov, de grootste blunder (belegging) van mij ooit.
    Boef Marius Ritskes kreeg ook korting (12%) bij een donatie aan het bedrijf met zijn Quivest.
    Nog dezelfde dag dumpte hij zijn aandelen op de beurs.
    Verwatering op verwatering.
    Al die domme newbies die hier rondhangen als maffe groupies, hebben nog nooit van Antonov gehoord.
  8. forum rang 10 DeZwarteRidder 19 juni 2018 19:43
    Daarom hier een korte samenvatting:
    ------------------------------------------------------------

    Antonov stond genoteerd aan de beurzen van Londen en Amsterdam sinds respectievelijk 1995 en 1997. Het bedrijf had vestigingen in Nederland, China en het Verenigd Koninkrijk, alwaar een centrum voor onderzoek en ontwikkeling was gehuisvest.

    Het bedrijf was omstreden omdat het sinds de oprichting nauwelijks omzet heeft geboekt. Om haar activiteiten te kunnen financieren had het bedrijf in het verleden regelmatig nieuw kapitaal verworven door emissies van nieuwe aandelen.

    De onderneming genoot vooral bekendheid omdat zij een geliefd gespreksonderwerp was onder beursspeculanten. Sceptici wezen daarbij op het uitblijven van commerciële successen, vertragingen bij het productierijp maken van de bakken, en het mislukken van eerdere soortgelijke bedrijven. Positievelingen (believers) wezen op de technologische voordelen, het winstpotentieel en gaven aan dat lange doorlooptijden gebruikelijk zijn bij technologische innovatie. Door beide kampen werd het aandeel niettemin als speculatief aangemerkt. Op online beleggersfora was het aandeel regelmatig onderwerp van verhitte discussies.
  9. forum rang 10 DeZwarteRidder 19 juni 2018 19:48
    Antonov lijkt bijzonder veel op Esperite:
    ----------------------------------------------------------------
    Delisting

    Op 30-04-2013 werd aangekondigd[1] dat het bedrijf op 29-05-2013 van de Amsterdamse beurs zal verdwijnen. Antonov was al op het 'strafbankje' geplaatst sinds 22-05-2012. Het bedrijf kon niet meer aan de beursregels voor de handel in zijn aandelen en aan de rapportageverplichtingen voldoen, waaronder het publiceren van jaarverslagen over 2011 en 2012 en een nieuwe prospectus. De aandelenkoers op 30-04-2013 was € 0,01.

    Verdwenen
    Antonov lijkt niet meer actief, nadat in 2011 nog een 3-speed versnellingsbak voor elektrische auto's werd aangekondigd.
  14. [verwijderd] 20 juni 2018 11:45
    Esperite N.V. secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologies
    GlobeNewswireJune 19, 2018
    Total investment can reach EUR 7.25 million upon exercise of share subscription warrants

    Amsterdam, The Netherlands - 19 June 2018

    Transaction highlights

    Potential financing of up to EUR 5 million through private placements of convertible notes with share subscription warrants attached over the next 24 months, subject to fulfilment of certain conditions

    Upon the exercise of all share subscription warrants, the total investment can reach EUR 7.25 million

    Subscription by European Select Growth Opportunities Fund, based in Australia

    Esperite to convene a general meeting to present the details of the financing to its shareholders and to propose to approve the issuance of tranches of convertible notes with share subscription warrants attached

    Proceeds to be used to support Esperite`s commercial activities and development of innovative technologies in the field of genetics, data-driven medicine, regenerative medicine and Immuno-therapeutic drugs

    Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces today having entered into a second issuance agreement with European Select Growth Opportunities Fund ("ESGO" or the "Investor), following the discussions announced on June 12, 2018 regarding a new external financing (the "Issuance Agreement").

    Pursuant to the Issuance Agreement, the Investor has committed to subscribe for an amount of up to EUR 5 million of convertible notes (the "Notes") with share subscription warrants attached (the "Warrants"), in several tranches over the 24 months following the issuance of the first tranche, subject to the fulfilment of certain conditions, including shareholders` approval by the general meeting of Esperite for the issuance of the Notes and Warrants to the Investor. The issuance of and subscription to the Notes and Warrants will be structured through the issuance by Esperite to the Investor of tranche warrants (the "Tranche Warrants"), whose characteristics are described in Appendix 1 to this press release.

    This new external financing is in addition to the earlier issuance agreement of up to EUR 9 million (plus EUR 4.05 million in case of exercise of all share subscription warrants) entered into between Esperite and the Investor on March 8, 2017 (the "2017 Issuance Agreement"). Under the 2017 Issuance Agreement, EUR 6.85 million of convertible notes have been issued, leaving EUR 2.15 million still available for issuance by Esperite.

    Characteristics of the Notes and of the Warrants

    The Notes have a principal amount of EUR 10,000 each and will be subscribed for with an initial tranche of EUR 300,000 and subsequent tranches of EUR 250,000 (unless increased or decreased upon mutual consent of Esperite and the Investor). The Notes bear no interest and have a maturity of 12 months from their issuance. During their term, the Investor may request to convert any or all of the Notes at a price equal to the lowest daily VWAP over the 10 consecutive trading days preceding the conversion request, minus a 6% discount (it being specified that days during which the Investor will have traded shares on the market will be excluded).

    Upon such conversion request, Esperite shall have the option to remit at its discretion, cash, shares in the capital of the Company or a combination of both.

    The Warrants have a maturity of 5 years from their issuance date and will be immediately detached from the Notes. Each Warrant will give right to subscribe for 1 new share in Esperite at a price equal to 115% of the lowest daily VWAP over the 10 consecutive trading days preceding the request from Esperite to issue the applicable tranche.

    Esperite can request the Investor to subscribe a tranche every 3 months (or earlier to the extent all outstanding Notes have been converted or redeemed).

    The Investor can subscribe to tranches at its discretion within the first EUR 2.5 million of the EUR 5 million commitment.

    Furthermore, the terms of the Notes and Warrants include: (i) customary business and compliance covenants; (ii) early redemption events; and (iii) standard anti-dilution mechanisms.

    Detailed terms and conditions of the Notes and the Warrants are set forth in Appendix 1 to this press release.

    At the next general meeting, Esperite will present the details of the new external financing to its shareholders and the shareholders will be asked to resolve to approve the issuance of the Notes and Warrants.

    ***

    About ESPERITE

    ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.

    To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.com, www.genoma.com and www.cryo-save.com.

    ***
  15. forum rang 10 DeZwarteRidder 20 juni 2018 12:05
    quote:

    Snaarwegger schreef op 20 juni 2018 11:45:

    Esperite N.V. secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologies
    GlobeNewswireJune 19, 2018
    Total investment can reach EUR 7.25 million upon exercise of share subscription warrants

    Amsterdam, The Netherlands - 19 June 2018
    Transaction highlights

    Potential financing of up to EUR 5 million through private placements of convertible notes with share subscription warrants attached over the next 24 months, subject to fulfilment of certain conditions
    Upon the exercise of all share subscription warrants, the total investment can reach EUR 7.25 million

    Subscription by European Select Growth Opportunities Fund, based in Australia
    Esperite to convene a general meeting to present the details of the financing to its shareholders and to propose to approve the issuance of tranches of convertible notes with share subscription warrants attached

    Proceeds to be used to support Esperite`s commercial activities and development of innovative technologies in the field of genetics, data-driven medicine, regenerative medicine and Immuno-therapeutic drugs

    Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces today having entered into a second issuance agreement with European Select Growth Opportunities Fund ("ESGO" or the "Investor), following the discussions announced on June 12, 2018 regarding a new external financing (the "Issuance Agreement").

    Pursuant to the Issuance Agreement, the Investor has committed to subscribe for an amount of up to EUR 5 million of convertible notes (the "Notes") with share subscription warrants attached (the "Warrants"), in several tranches over the 24 months following the issuance of the first tranche, subject to the fulfilment of certain conditions, including shareholders` approval by the general meeting of Esperite for the issuance of the Notes and Warrants to the Investor. The issuance of and subscription to the Notes and Warrants will be structured through the issuance by Esperite to the Investor of tranche warrants (the "Tranche Warrants"), whose characteristics are described in Appendix 1 to this press release.

    This new external financing is in addition to the earlier issuance agreement of up to EUR 9 million (plus EUR 4.05 million in case of exercise of all share subscription warrants) entered into between Esperite and the Investor on March 8, 2017 (the "2017 Issuance Agreement"). Under the 2017 Issuance Agreement, EUR 6.85 million of convertible notes have been issued, leaving EUR 2.15 million still available for issuance by Esperite.

    Characteristics of the Notes and of the Warrants

    The Notes have a principal amount of EUR 10,000 each and will be subscribed for with an initial tranche of EUR 300,000 and subsequent tranches of EUR 250,000 (unless increased or decreased upon mutual consent of Esperite and the Investor). The Notes bear no interest and have a maturity of 12 months from their issuance. During their term, the Investor may request to convert any or all of the Notes at a price equal to the lowest daily VWAP over the 10 consecutive trading days preceding the conversion request, minus a 6% discount (it being specified that days during which the Investor will have traded shares on the market will be excluded).

    Upon such conversion request, Esperite shall have the option to remit at its discretion, cash, shares in the capital of the Company or a combination of both.

    The Warrants have a maturity of 5 years from their issuance date and will be immediately detached from the Notes. Each Warrant will give right to subscribe for 1 new share in Esperite at a price equal to 115% of the lowest daily VWAP over the 10 consecutive trading days preceding the request from Esperite to issue the applicable tranche.

    Esperite can request the Investor to subscribe a tranche every 3 months (or earlier to the extent all outstanding Notes have been converted or redeemed).

    The Investor can subscribe to tranches at its discretion within the first EUR 2.5 million of the EUR 5 million commitment.

    Furthermore, the terms of the Notes and Warrants include: (i) customary business and compliance covenants; (ii) early redemption events; and (iii) standard anti-dilution mechanisms.

    Detailed terms and conditions of the Notes and the Warrants are set forth in Appendix 1 to this press release.

    At the next general meeting, Esperite will present the details of the new external financing to its shareholders and the shareholders will be asked to resolve to approve the issuance of the Notes and Warrants.
    ***About ESPERITE
    ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
    To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.com, www.genoma.com and www.cryo-save.com.***
    Dit is oud nieuws en dus MISLIJDEND....!!!
3.239 Posts
Pagina: «« 1 ... 87 88 89 90 91 ... 162 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
HEIJMANS KON 26,450 +2,95 +12,55%
Basic-Fit 23,500 +2,04 +9,51%
EBUSCO HOLDING 1,386 +0,11 +8,37%
RENEWI 8,080 +0,28 +3,59%
Vopak 41,920 +1,34 +3,30%
Arcadis 66,050 +2,05 +3,20%
ADYEN NV 1.083,600 +32,40 +3,08%
ASML 820,500 +20,90 +2,61%
BAM 4,180 +0,10 +2,55%
Sligro 12,120 +0,26 +2,19%
ASCX 1.261,09 +25,55 +2,07%
Brunel 10,340 +0,18 +1,77%
Fugro 24,460 +0,42 +1,75%
BESI 122,900 +2,10 +1,74%
ACOMO 17,500 +0,26 +1,51%
Corbion 20,460 +0,30 +1,49%
CM.COM 7,710 +0,11 +1,45%
ASR Nederland 46,120 +0,65 +1,43%
B&S Group SA 4,750 +0,07 +1,39%
UNILEVER PLC 56,140 +0,72 +1,30%
Ahold Delhaize 29,770 +0,38 +1,29%
Heineken 90,700 +1,02 +1,14%
Avantium 2,475 +0,02 +1,02%
NX FILTRATION 5,560 +0,05 +0,91%
AEX 906,64 +8,07 +0,90%
Aegon 5,868 +0,05 +0,89%
Wolters Kluwer 156,100 +1,35 +0,87%
PostNL 1,403 +0,01 +0,86%
Vastned 23,550 +0,20 +0,86%
IMCD 131,250 +1,10 +0,85%
ASMI 605,600 +4,60 +0,77%
RANDSTAD NV 45,260 +0,31 +0,69%
THEON INTERNAT 12,120 +0,08 +0,66%
JDE PEET'S 18,390 +0,12 +0,66%
Fagron 18,780 +0,12 +0,64%
Van Lanschot Kempen NV 40,100 +0,25 +0,63%
JUST EAT TAKEAWAY 10,845 +0,07 +0,60%
TomTom 5,150 +0,03 +0,59%
RELX 42,880 +0,22 +0,52%
EXOR NV 93,050 +0,45 +0,49%
ALLFUNDS GROUP 5,235 +0,03 +0,48%
ING 17,018 +0,08 +0,45%
SHELL PLC 33,065 +0,14 +0,43%
CTP 16,100 +0,06 +0,37%
AMG Critical Materials N.V. 15,100 +0,03 +0,20%
ABN AMRO BANK N.V. 16,425 +0,03 +0,15%
Wereldhave 13,840 +0,02 +0,14%
DSM FIRMENICH AG 111,200 +0,15 +0,14%
SBM Offshore 14,640 +0,01 +0,07%
NN Group 45,870 +0,03 +0,07%
Accsys 0,641 0,00 0,00%
Air France-KLM 8,332 0,00 0,00%
Eurocommercial Properties 22,850 0,00 0,00%
ForFarmers 2,920 0,00 0,00%
NSI 19,340 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Flow Traders 15,190 -4,01 -20,89%
SIGNIFY NV 22,420 -1,74 -7,20%
WDP 24,960 -0,94 -3,63%
Alfen N.V. 16,175 -0,45 -2,74%
Sif Holding 12,280 -0,22 -1,76%
UMG 21,340 -0,36 -1,66%
KPN 3,634 -0,06 -1,62%
Nedap N.V. 58,200 -0,80 -1,36%
Akzo Nobel 56,680 -0,74 -1,29%
Philips Koninklijke 23,740 -0,20 -0,84%
OCI 22,120 -0,16 -0,72%
AALBERTS NV 36,100 -0,22 -0,61%
TKH 40,380 -0,22 -0,54%
Kendrion 12,520 -0,06 -0,48%
INPOST 15,300 -0,07 -0,46%
AMX 871,07 -2,69 -0,31%
AZERION 1,570 0,00 -0,25%
Galapagos 25,140 -0,06 -0,24%
FASTNED 16,880 -0,04 -0,24%
ArcelorMittal 20,740 -0,03 -0,14%
Pharming 0,769 0,00 -0,13%
Aperam 24,920 -0,02 -0,08%
PROSUS 31,745 -0,02 -0,06%
NEEM NU EEN ABONNEMENT OP IEX PREMIUM > NU 3 MAANDEN VOOR SLECHTS €24,95!
vlag naam koers verschil relatief verschil
AEX 906,64 +8,07 +0,90%
AEX GR 3.518,51 +32,34 +0,93%
Germany40^ 18.466,50 +167,78 +0,92%
FTSE 100 8.285,71 +99,36 +1,21%
EURO50 4.875,53 0,00 0,00%
US30^ 40.597,00 0,00 0,00%
Nasd100^ 19.034,30 0,00 0,00%
US500^ 5.461,10 0,00 0,00%
Japan225^ 38.252,20 0,00 0,00%
VD-NEW 15,06 -0,66 -4,22%
#/^ Index indications calculated real time, zie disclaimer